186 related articles for article (PubMed ID: 29238168)
1. The role of maintenance therapy in the treatment of elderly non-small-cell lung cancer patients: a meta-analysis of randomized controlled trials.
Zhang L; Gao S; He J
Drug Des Devel Ther; 2017; 11():3435-3440. PubMed ID: 29238168
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and toxicities of combination maintenance therapy in the treatment of advanced non-small-cell lung cancer: an up-to-date meta-analysis.
Hu J; Hu J; Liu X; Li L; Bai X
Biosci Rep; 2019 Jun; 39(6):. PubMed ID: 31015373
[No Abstract] [Full Text] [Related]
3. Maintenance Therapy Improves Survival Outcomes in Patients with Advanced Non-small Cell Lung Cancer: A Meta-analysis of 14 Studies.
Lu S; Yu Y; Chen Z; Ye X; Li Z; Niu X
Lung; 2015 Oct; 193(5):805-14. PubMed ID: 26119960
[TBL] [Abstract][Full Text] [Related]
4. Comparative effectiveness of combined therapy inhibiting EGFR and VEGF pathways in patients with advanced non-small-cell lung cancer: a meta-analysis of 16 phase II/III randomized trials.
Zhao Y; Wang H; Shi Y; Cai S; Wu T; Yan G; Cheng S; Cui K; Xi Y; Qi X; Zhang J; Ma W
Oncotarget; 2017 Jan; 8(4):7014-7024. PubMed ID: 27690345
[TBL] [Abstract][Full Text] [Related]
5. Doublet vs Single-Agent Maintenance Therapy in the Treatment of Non-Small-Cell Lung Cancer: A Meta-Analysis.
Qi J; Guo X; Li A
Drug Des Devel Ther; 2020; 14():2179-2185. PubMed ID: 32606590
[TBL] [Abstract][Full Text] [Related]
6. Efficacy of targeted agents in the treatment of elderly patients with advanced non-small-cell lung cancer: a systematic review and meta-analysis.
Chen J; Chen J; Wu X; Shi T; Kang M
Onco Targets Ther; 2016; 9():4797-803. PubMed ID: 27536143
[TBL] [Abstract][Full Text] [Related]
7. Maintenance or Consolidation Therapy for Non--Small-Cell Lung Cancer: A Meta-Analysis Involving 5841 Subjects.
Zhang C; Huang C; Wang J; Wang X; Li K
Clin Lung Cancer; 2015 Sep; 16(5):e15-23. PubMed ID: 25676720
[TBL] [Abstract][Full Text] [Related]
8. The efficacy and safety of pemetrexed-based doublet therapy compared to pemetrexed alone for the second-line treatment of advanced non-small-cell lung cancer: an updated meta-analysis.
Zhong A; Xiong X; Shi M; Xu H
Drug Des Devel Ther; 2015; 9():3685-93. PubMed ID: 26229433
[TBL] [Abstract][Full Text] [Related]
9. Efficacy of combining targeted therapy with pemetrexed or docetaxel as second-line treatment in patients with advanced non-small-cell lung cancer: a meta-analysis of 14 randomized controlled trials.
Li X; Wang H; Lin W; Xu Q
Curr Med Res Opin; 2014 Nov; 30(11):2295-304. PubMed ID: 24701984
[TBL] [Abstract][Full Text] [Related]
10. Meta-analysis comparing doublet and single cytotoxic agent therapy as first-line treatment in elderly patients with advanced nonsmall-cell lung cancer.
Wang S; Wang Q; Tian J; Zhou Z; Jiao L; Fu Y; Chen S; Zhang J; Xu L
J Int Med Res; 2015 Dec; 43(6):727-37. PubMed ID: 26438014
[TBL] [Abstract][Full Text] [Related]
11. Comparison of the efficacy and safety of single-agent and doublet chemotherapy in advanced non-small cell lung cancer in the elderly: a meta-analysis.
Des Guetz G; Uzzan B; Nicolas P; Valeyre D; Sebbane G; Morere JF
Crit Rev Oncol Hematol; 2012 Dec; 84(3):340-9. PubMed ID: 22534083
[TBL] [Abstract][Full Text] [Related]
12. The role of angiogenesis inhibitors in the treatment of elderly patients with advanced non-small-cell lung cancer: A meta-analysis of eleven randomized controlled trials.
Tian RH; Wu X; Liu X; Yang JW; Ji HL; Yan YJ
J Cancer Res Ther; 2016; 12(2):571-5. PubMed ID: 27461612
[TBL] [Abstract][Full Text] [Related]
13. Meta-analysis of docetaxel-based doublet versus docetaxel alone as second-line treatment for advanced non-small-cell lung cancer.
Qi WX; Shen Z; Yao Y
Cancer Chemother Pharmacol; 2012 Jan; 69(1):99-106. PubMed ID: 21607554
[TBL] [Abstract][Full Text] [Related]
14. The Efficacy of Single-Agent Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Therapy in Biologically Selected Patients with Non-Small-Cell Lung Cancer: A Meta-Analysis of 19 Randomized Controlled Trials.
Li G; Gao S; Sheng Z; Li B
Chemotherapy; 2016; 61(4):179-89. PubMed ID: 26859739
[TBL] [Abstract][Full Text] [Related]
15. Meta-analysis of single-agent chemotherapy compared with combination chemotherapy as second-line treatment of advanced non-small-cell lung cancer.
Di Maio M; Chiodini P; Georgoulias V; Hatzidaki D; Takeda K; Wachters FM; Gebbia V; Smit EF; Morabito A; Gallo C; Perrone F; Gridelli C
J Clin Oncol; 2009 Apr; 27(11):1836-43. PubMed ID: 19273711
[TBL] [Abstract][Full Text] [Related]
16. [Intercalated Combination of Chemotherapy and EGFR-TKIs versus Chemotherapy Alone in the First-line Treatment of Advanced Non-small Cell Lung Cancer: A Meta-analysis].
Hong C; Mei T; Wang J
Zhongguo Fei Ai Za Zhi; 2016 Dec; 19(12):837-846. PubMed ID: 27978869
[TBL] [Abstract][Full Text] [Related]
17. Efficacy of erlotinib in patients with advanced non-small cell lung cancer: a pooled analysis of randomized trials.
Gao H; Ding X; Wei D; Cheng P; Su X; Liu H; Aziz F; Wang D; Zhang T
Anticancer Drugs; 2011 Oct; 22(9):842-52. PubMed ID: 21808188
[TBL] [Abstract][Full Text] [Related]
18. Overall response rate, progression-free survival, and overall survival with targeted and standard therapies in advanced non-small-cell lung cancer: US Food and Drug Administration trial-level and patient-level analyses.
Blumenthal GM; Karuri SW; Zhang H; Zhang L; Khozin S; Kazandjian D; Tang S; Sridhara R; Keegan P; Pazdur R
J Clin Oncol; 2015 Mar; 33(9):1008-14. PubMed ID: 25667291
[TBL] [Abstract][Full Text] [Related]
19. The addition of anti-angiogenic tyrosine kinase inhibitors to chemotherapy for patients with advanced non-small-cell lung cancers: A meta-analysis of randomized trials.
Li BT; Barnes TA; Chan DL; Naidoo J; Lee A; Khasraw M; Marx GM; Kris MG; Clarke SJ; Drilon A; Rudin CM; Pavlakis N
Lung Cancer; 2016 Dec; 102():21-27. PubMed ID: 27987583
[TBL] [Abstract][Full Text] [Related]
20. The Efficacy of Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors for Molecularly Selected Patients with Non-Small Cell Lung Cancer: A Meta-Analysis of 30 Randomized Controlled Trials.
Liu J; Sheng Z; Zhang Y; Li G
Target Oncol; 2016 Feb; 11(1):49-58. PubMed ID: 26206590
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
